Finally, as next generation sequencing panels are commonly used at acute myeloid leukemia diagnosis to evaluate multiple clinically relevant markers, next generation sequencing may be the sole FLT3 test required if its performance can demonstrate comparability to the standard fragment analysis test, and the turn-around-time can meet clinical needs. This evidence concerns the gene FLT3 and acute myeloid leukemia.